BFPW
HIV

BOK Financial Private Wealth’s CALYPTE BIOMEDICAL CORP NEW HIV Stock Holding History

BOK Financial Private Wealth’s Portfolio HIV Stock Details HIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-595,888
Closed – – 453
2022
Q1 		$0 Hold
595,888
– – ﹤0.01% 341
2021
Q4 		$0 Hold
595,888
– – ﹤0.01% 314
2021
Q3 		$0 Hold
595,888
– – ﹤0.01% 251
2021
Q2 		$0 Hold
595,888
– – ﹤0.01% 233
2021
Q1 		$0 Hold
595,888
– – ﹤0.01% 208
2020
Q4 		$0 Buy
+595,888
New – ﹤0.01% 191
2020
Q3 		– Sell
-595,888
Closed – – 176
2020
Q2 		$0 Hold
595,888
– – ﹤0.01% 198
2020
Q1 		$0 Hold
595,888
– – ﹤0.01% 209
2019
Q4 		$0 Buy
+595,888
New – ﹤0.01% 194

BOK Financial Private Wealth's HIV Position: Q2 2022 in Review

BOK Financial Private Wealth sold out of CALYPTE BIOMEDICAL CORP NEW (HIV) in Q2 2022, closing a stake of 595,888 shares.

BOK Financial Private Wealth first reported a position in HIV in Q4 2019 and held it in 9 quarters. The position peaked at $0 in Q1 2022. 0 funds tracked by Wall St. Rank hold HIV as of Q2 2022.

  • BOK Financial Private Wealth reported no remaining CALYPTE BIOMEDICAL CORP NEW position as of Q2 2022 after selling out during the quarter.
  • BOK Financial Private Wealth sold 595,888 CALYPTE BIOMEDICAL CORP NEW shares in Q2 2022.
  • BOK Financial Private Wealth first reported a position in CALYPTE BIOMEDICAL CORP NEW in Q4 2019 and held it in 9 quarters.
  • BOK Financial Private Wealth's CALYPTE BIOMEDICAL CORP NEW position peaked at $0 in Q1 2022.
  • 0 funds tracked by Wall St. Rank held CALYPTE BIOMEDICAL CORP NEW as of Q2 2022.

Based on BOK Financial Private Wealth's 13F filing for Q2 2022, filed 15 Aug 2022.